Immatics (IMTX) Liabilities and Shareholders Equity (2019 - 2025)

Immatics (IMTX) reported Liabilities and Shareholders Equity of $654.6 million for Q4 2025, down 12.01% on a YoY basis from $743.9 million in Q4 2024, and up 7.98% sequentially from $606.2 million in Q3 2025.

Immatics (IMTX) Liabilities and Shareholders Equity (2019 - 2025) Analysis & Trends

Immatics (IMTX) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $654.6 million in Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 12.01% year-over-year to $654.6 million; the trailing twelve-month figure through Dec 2025 stood at $2.6 billion (down 6.68% YoY), and the FY2025 full-year result was $635.3 million, down 15.68% from the prior year.
  • Liabilities and Shareholders Equity rose to $654.6 million in Q4 2025, from $606.2 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $743.9 million in Q4 2024 to a low of $199.8 million in Q4 2021.
  • A 5-year average of $484.2 million and a median of $461.4 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
  • Peak annual rise in Liabilities and Shareholders Equity reached 119.32% in 2021, while the deepest fall reached 34.2% in 2021.
  • Tracing IMTX's Liabilities and Shareholders Equity over 5 years: stood at $199.8 million in 2021, then surged by 108.26% to $416.1 million in 2022, then surged by 31.87% to $548.7 million in 2023, then soared by 35.58% to $743.9 million in 2024, then declined by 12.01% to $654.6 million in 2025.
  • Business Quant data shows IMTX's Liabilities and Shareholders Equity at $654.6 million in Q4 2025, $606.2 million in Q3 2025, and $642.2 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 Immatics 1.14 Bn 1.14 Bn - 654.58 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 654.58 Mn
Sep 30, 2025 606.22 Mn
Jun 30, 2025 642.16 Mn
Mar 31, 2025 674.99 Mn
Dec 31, 2024 743.90 Mn
Sep 30, 2024 633.93 Mn
Jun 30, 2024 675.17 Mn
Mar 31, 2024 709.53 Mn
Dec 31, 2023 548.69 Mn
Sep 30, 2023 476.20 Mn
Jun 30, 2023 446.66 Mn
Mar 31, 2023 406.25 Mn
Dec 31, 2022 416.08 Mn
Sep 30, 2022 357.22 Mn
Jun 30, 2022 393.00 Mn
Mar 31, 2022 316.70 Mn
Dec 31, 2021 199.79 Mn
Sep 30, 2021 234.57 Mn
Jun 30, 2021 260.73 Mn
Mar 31, 2021 286.81 Mn